Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis

Stan L. Block, Ram Yogev, Felix Waldmeier, Kamal Hamed

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

An open-label study evaluated the safety (n = 53) and pharmacokinetics (n = 8) of single-dose therapy with 1500 mg famciclovir (prodrug of penciclovir) for recurrent herpes labialis in adolescents. Mean Cmax, mean AUC0-, and clearance for penciclovir were 9.37 μg/mL, 31.8 μg • h/mL, and 38.2 L/h, respectively, and within the range extrapolated from data in adults. Adverse events were generally mild and transient.

Original languageEnglish (US)
Pages (from-to)525-528
Number of pages4
JournalPediatric Infectious Disease Journal
Volume30
Issue number6
DOIs
StatePublished - Jan 1 2011

Keywords

  • adolescent
  • famciclovir
  • herpes labialis
  • pharmacokinetics
  • safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis'. Together they form a unique fingerprint.

  • Cite this